NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University Hospital, Essen
Sun Yat-sen University
University of Cologne
Fujian Cancer Hospital
Case Comprehensive Cancer Center
University of Aleppo
Sun Yat-sen University
Fujian Cancer Hospital
Ludwig-Maximilians - University of Munich
National Cancer Institute, Naples
First Affiliated Hospital of Zhejiang University
Hospital Israelita Albert Einstein
Changhai Hospital
Catharina Ziekenhuis Eindhoven
Shandong Cancer Hospital and Institute
Shanghai Henlius Biotech
Fudan University
Nanfang Hospital, Southern Medical University
Eastern Cooperative Oncology Group
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Fujian Cancer Hospital
Salah Azaïz Cancer Institute
Cinnagen
National Cancer Institute, Naples
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Zhujiang Hospital
Zhujiang Hospital
Sixth Affiliated Hospital, Sun Yat-sen University
Zealand University Hospital
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Tanta University
City Clinical Oncology Hospital No 1
Ludwig-Maximilians - University of Munich
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Akeso
University of Southern California
The First Affiliated Hospital with Nanjing Medical University
Shanghai Zhongshan Hospital
Sun Yat-sen University
Shanghai Minimally Invasive Surgery Center
Alliance for Clinical Trials in Oncology
Assiut University
Tarveda Therapeutics
First Affiliated Hospital of Wenzhou Medical University
Australasian Gastro-Intestinal Trials Group
CSPC Ouyi Pharmaceutical Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital
Khon Kaen University